T N Peel1, A C Cheng, Y P Lorenzo, D C M Kong, K L Buising, P F M Choong. 1. Department of Surgery, St Vincent's Hospital Melbourne, University of Melbourne, Victoria 3065, Australia; Department of Infectious Diseases, St Vincent's Hospital Melbourne, Victoria, Australia; Department of Orthopaedic Surgery, St Vincent's Hospital Melbourne, Victoria, Australia. Electronic address: tnpeel@unimelb.edu.au.
Abstract
BACKGROUND: Prosthetic joint infection (PJI) is associated with significant costs to the healthcare system. Current literature examines the cost of specific treatment modalities without assessing other cost drivers for PJI. AIMS: To examine the overall cost of the treatment of PJI and to identify factors associated with management costs. METHODS: The costs of treatment of prosthetic joint infections were examined in 139 patients across 10 hospitals over a 3-year period (January 2006 to December 2008). Cost calculations included hospitalization costs, surgical costs, hospital-in-the-home costs and antibiotic therapy costs. Negative binomial regression analysis was performed to model factors associated with total cost. FINDINGS: The median cost of treating prosthetic joint infection per patient was Australian $34,800 (interquartile range: 20,305, 56,929). The following factors were associated with increased treatment costs: septic revision arthroplasty (67% increase in treatment cost; P = 0.02), hypotension at presentation (70% increase; P = 0.03), polymicrobial infections (41% increase; P = 0.009), surgical treatment with one-stage exchange (100% increase; P = 0.002) or resection arthroplasty (48% increase; P = 0.001) were independently associated with increased treatment costs. Culture-negative prosthetic joint infections were associated with decreased costs (29% decrease in treatment cost; P = 0.047). Treatment failure was associated with 156% increase in treatment costs. CONCLUSIONS: This study identifies clinically important factors influencing treatment costs that may be of relevance to policy-makers, particularly in the setting of hospital reimbursement and guiding future research into cost-effective preventive strategies.
BACKGROUND: Prosthetic joint infection (PJI) is associated with significant costs to the healthcare system. Current literature examines the cost of specific treatment modalities without assessing other cost drivers for PJI. AIMS: To examine the overall cost of the treatment of PJI and to identify factors associated with management costs. METHODS: The costs of treatment of prosthetic joint infections were examined in 139 patients across 10 hospitals over a 3-year period (January 2006 to December 2008). Cost calculations included hospitalization costs, surgical costs, hospital-in-the-home costs and antibiotic therapy costs. Negative binomial regression analysis was performed to model factors associated with total cost. FINDINGS: The median cost of treating prosthetic joint infection per patient was Australian $34,800 (interquartile range: 20,305, 56,929). The following factors were associated with increased treatment costs: septic revision arthroplasty (67% increase in treatment cost; P = 0.02), hypotension at presentation (70% increase; P = 0.03), polymicrobial infections (41% increase; P = 0.009), surgical treatment with one-stage exchange (100% increase; P = 0.002) or resection arthroplasty (48% increase; P = 0.001) were independently associated with increased treatment costs. Culture-negative prosthetic joint infections were associated with decreased costs (29% decrease in treatment cost; P = 0.047). Treatment failure was associated with 156% increase in treatment costs. CONCLUSIONS: This study identifies clinically important factors influencing treatment costs that may be of relevance to policy-makers, particularly in the setting of hospital reimbursement and guiding future research into cost-effective preventive strategies.
Authors: Maria Dudareva; Lucinda Barrett; Mel Figtree; Matthew Scarborough; Masanori Watanabe; Robert Newnham; Rachael Wallis; Sarah Oakley; Ben Kendrick; David Stubbs; Martin A McNally; Philip Bejon; Bridget A Atkins; Adrian Taylor; Andrew J Brent Journal: J Clin Microbiol Date: 2018-11-27 Impact factor: 5.948
Authors: Pierre Chauvelot; Tristan Ferry; Virginie Tafani; Alan Diot; Jason Tasse; Anne Conrad; Christian Chidiac; Evelyne Braun; Sébastien Lustig; Frédéric Laurent; Florent Valour Journal: Front Med (Lausanne) Date: 2021-01-21
Authors: Kirsty Garfield; Sian Noble; Erik Lenguerrand; Michael R Whitehouse; Adrian Sayers; Mike R Reed; Ashley W Blom Journal: BMC Med Date: 2020-11-18 Impact factor: 8.775
Authors: Martin H Thornhill; Annabel Crum; Saleema Rex; Tony Stone; Richard Campbell; Mike Bradburn; Veronica Fibisan; Peter B Lockhart; Bryan Springer; Larry M Baddour; Jon Nicholl Journal: JAMA Netw Open Date: 2022-01-04